Published in Neoplasia on July 01, 2008
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A (2012) 1.80
Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature (2016) 1.47
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia (2009) 1.39
Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway. PLoS One (2011) 1.27
Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc Natl Acad Sci U S A (2012) 1.23
Frizzled7 as an emerging target for cancer therapy. Cell Signal (2011) 1.16
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest (2014) 1.16
Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br J Cancer (2009) 1.14
JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia (2009) 1.10
Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active β-catenin. Oncogene (2010) 1.04
Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol Cancer (2011) 1.03
Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting. BMC Cancer (2009) 0.92
Planar cell polarity signaling in collective cell movements during morphogenesis and disease. Curr Genomics (2012) 0.91
Frizzled homolog proteins, microRNAs and Wnt signaling in cancer. Int J Cancer (2012) 0.89
MiR-199a regulates cell proliferation and survival by targeting FZD7. PLoS One (2014) 0.89
Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells. Oncogenesis (2012) 0.88
Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal (2012) 0.87
Linkage to chromosome 2q32.2-q33.3 in familial serrated neoplasia (Jass syndrome). Fam Cancer (2011) 0.87
Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation. Cancer Lett (2013) 0.85
Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. PLoS One (2014) 0.84
Stage of breast cancer progression influences cellular response to activation of the WNT/planar cell polarity pathway. Sci Rep (2014) 0.83
Evidence for the importance of personalized molecular profiling in pancreatic cancer. Pancreas (2014) 0.83
Wnt-signalling pathways and microRNAs network in carcinogenesis: experimental and bioinformatics approaches. Mol Cancer (2016) 0.82
Frizzled 7 expression is positively regulated by SIRT1 and β-catenin in breast cancer cells. PLoS One (2014) 0.81
Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models. ERJ Open Res (2015) 0.81
FZD6 expression is negatively regulated by miR-199a-5p in human colorectal cancer. BMB Rep (2015) 0.79
Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ. Oncotarget (2016) 0.79
Structure-based Discovery of Novel Small Molecule Wnt Signaling Inhibitors by Targeting the Cysteine-rich Domain of Frizzled. J Biol Chem (2015) 0.78
RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines. Int J Clin Exp Pathol (2014) 0.78
Pharmacological folding chaperones act as allosteric ligands of Frizzled4. Nat Chem Biol (2015) 0.77
ACE2 and FZD1 are prognosis markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of gallbladder. J Mol Histol (2013) 0.76
Frizzled2 signaling regulates growth of high-risk neuroblastomas by interfering with β-catenin-dependent and β-catenin-independent signaling pathways. Oncotarget (2016) 0.76
Dinosaurs and ancient civilizations: reflections on the treatment of cancer. Neoplasia (2010) 0.75
The War on Cancer rages on. Neoplasia (2009) 0.75
Neoplasia: the second decade. Neoplasia (2008) 0.75
FZD7 is a novel prognostic marker and promotes tumor metastasis via WNT and EMT signaling pathways in esophageal squamous cell carcinoma. Oncotarget (2017) 0.75
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 10.38
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res (1998) 5.80
Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene (2006) 4.14
Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology (2005) 4.09
Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol (1999) 4.04
The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene (1999) 3.95
Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A (1997) 3.79
APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci U S A (2000) 3.41
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell (2004) 3.30
Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene (2005) 2.06
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88
The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut (2006) 1.86
Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene (2002) 1.75
The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology (2006) 1.73
Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res (1999) 1.62
Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol (2008) 1.56
Syndecan-4 regulates non-canonical Wnt signalling and is essential for convergent and extension movements in Xenopus embryos. Nat Cell Biol (2006) 1.44
A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proc Natl Acad Sci U S A (1998) 1.42
Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol (2007) 1.40
Xenopus frizzled 7 can act in canonical and non-canonical Wnt signaling pathways: implications on early patterning and morphogenesis. Mech Dev (2000) 1.39
The human Frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt. beta-catenin signaling cascade. J Biol Chem (2004) 1.37
Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response. Oncogene (1999) 1.35
Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. Cancer Res (2004) 1.17
Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7. Biochem Biophys Res Commun (1998) 1.07
Frizzled-7 dictates three-dimensional organization of colorectal cancer cell carcinoids. Oncogene (2006) 1.05
Expression profiles of 10 members of Frizzled gene family in human gastric cancer. Int J Oncol (2001) 1.04
Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation (2005) 0.98
MethPrimer: designing primers for methylation PCRs. Bioinformatics (2002) 14.48
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A (2008) 6.38
Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A (2006) 4.90
Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 4.80
Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet (2003) 3.93
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res (2008) 3.81
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Hormonal, cellular, and molecular control of prostatic development. Dev Biol (2003) 2.67
Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res (2012) 2.45
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res (2010) 2.07
A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. Am J Gastroenterol (2012) 2.06
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene (2003) 1.91
A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod Rheumatol (2006) 1.91
DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology (2008) 1.83
DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog (2002) 1.83
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene (2005) 1.82
Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exocrinopathy). Autoimmun Rev (2004) 1.80
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res (2006) 1.73
MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer (2010) 1.70
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet (2004) 1.66
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood (2003) 1.65
Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res (2006) 1.65
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res (2008) 1.64
Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res (2002) 1.64
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene (2005) 1.62
Risk of malignancies in IgG4-related disease. Mod Rheumatol (2011) 1.61
In vivo oxygen radical generation in the skin of the protoporphyria model mouse with visible light exposure: an L-band ESR study. J Invest Dermatol (2004) 1.60
Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol (2004) 1.59
Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J (2002) 1.59
Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res (2005) 1.58
Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res (2008) 1.58
Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A (2003) 1.57
MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res (2011) 1.57
Intractable colitis associated with chronic granulomatous disease. J Med Microbiol (2006) 1.56
New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol (2002) 1.54
The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol (2003) 1.53
Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis (2007) 1.52
Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis (2010) 1.52
MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis (2011) 1.51
Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer (2003) 1.51
The p53 family member genes are involved in the Notch signal pathway. J Biol Chem (2001) 1.50
miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res (2012) 1.46
MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res (2006) 1.46
Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer (2008) 1.45
BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis (2009) 1.44
A new type of protein chip to detect hepatocellular carcinoma-related autoimmune antibodies in the sera of hepatitis C virus-positive patients. Proteome Sci (2013) 1.44
The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men. J Urol (2006) 1.43
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology (2004) 1.43
Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res (2006) 1.41
Usefulness of narrow-band imaging endoscopy for diagnosis of Barrett's esophagus. J Gastroenterol (2004) 1.40
Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res (2011) 1.40
Classification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc (2002) 1.40
Tophaceous gout in the cervical spine. Intern Med (2012) 1.40
Antitumor effect of dsRNA-induced p21(WAF1/CIP1) gene activation in human bladder cancer cells. Mol Cancer Ther (2008) 1.39
Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer (2006) 1.37
Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One (2012) 1.35
PGDB: a curated and integrated database of genes related to the prostate. Nucleic Acids Res (2003) 1.35
IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis (2009) 1.34
Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation (2009) 1.34
Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol (2011) 1.33
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol (2012) 1.31
Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila) (2011) 1.30
The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology (2005) 1.30
MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One (2013) 1.27
Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res (2003) 1.27
Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res (2005) 1.26
Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One (2012) 1.26
Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol (2008) 1.26
MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res (2007) 1.25
Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol (2008) 1.25
Association of the -173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol (2004) 1.25
Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res (2005) 1.25
Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer (2011) 1.24
Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst (2002) 1.24